Precigen clinical trials we track

Check company identity source

Phase 3 1 trial

TrialDrugs studiedStatusPrimary completion
Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in ChildrenNCT07901738Zopapogene imadenovec-drbaNot yet recruiting2029-01Estimated

Phase 2 1 trial

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Determine the Objective Response Rate (ORR) following treatment with PRGN-2009 in combination with pembrolizumab or pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.. After: Measure: Determine the Objective Response Rate (ORR) following treatment with PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer..

Planned enrollment decreased by 22 participants

Before: 46 participants (planned). After: 24 participants (planned).

Primary completion date changed

Before: 30 Jan 2028. After: 11 Nov 2026.

Check registry source